[Background] Ovarian teratomas are the most common ovarian tumors in
children. Fertility-sparing surgery (FSS) is often recommended owing to
its advantage of fertility preservation. We examined the validity of FSS
in pediatric patients with ovarian teratomas. [Procedure] We
retrospectively reviewed the medical records of patients who underwent
initial surgery for ovarian teratomas in our department between
1972–2021. Patients were divided into two groups: oophorectomy (OVX)
group and FSS group. Clinical characteristics, perioperative
characteristics, and outcomes were compared between the groups.
[Results] Forty-six patients underwent initial surgery (OVX: 25
patients; FSS: 21 patients). There were no differences between the
groups in terms of age, pathological diagnosis, affected side, ovarian
torsion, postoperative complications, recurrence rate, or length of
postoperative follow-up. Regarding pathological diagnosis, immature
teratomas were found only in the OVX group (p = 0.0161). The tumor size
was larger in the OVX group (p = 0.0104). Regarding perioperative
findings, operation time was longer in the FSS group (p = 0.0071) and
bleeding volume was higher in the OVX group (p = 0.0070). The number of
days until the start of oral intake and the length of hospital stay
postoperatively were shorter in the FSS group (p = 0.0002 and p
< 0.0001, respectively). [Conclusion] We demonstrated the
advantages of FSS, including its minimally invasive approach and
comparable outcomes in terms of tumor recurrence; the operation time was
longer. Since both FSS and OVX are associated with a risk of tumor
recurrence, long-term follow-up in anticipation of adult transition is
necessary.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.